# Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

> **NCT03893630** · PHASE2 · COMPLETED · sponsor: **John O'Brien, MD** · enrollment: 208 (actual)

## Conditions studied

- Pre-Eclampsia

## Interventions

- **DRUG:** Acetylsalicylic Acid 81 mg
- **DRUG:** Acetylsalicylic Acid 162 mg
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT03893630
- **Lead sponsor:** John O'Brien, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-25
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-09-28
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893630, "Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03893630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*